Hikma Pharmaceuticals
HIK.L · LSE · GBX · Healthcare
Price
+7.9% since 20/07/20263 months · High 1,754.69 p (-5.3%) · Low 1,483.69 p
What is happening
No dip right now: the price is at the 6-week high. How it continues – phase and signs – you see with a free account.
Free account · 3 stocks and coins a dayHow deep is the dip?
- from the 6-week high0.0%
Highest daily price: 1,662.00 p on 16/10/2026 · reference of the assessment
- from the 3-month high-5.3%
Highest daily price in 3 months: 1,754.69 p on 06/08/2026
- from the 52-week high-10.9%
Highest price in 52 weeks: 1,865.00 p (Yahoo)
Marking places no order – it only helps you keep track.
Catalysts
4 h ago- News, last 10 days
- no recent news
- Next earnings
- —
- Last report
- —
Trade levels
Why the engine says so
History for this stock or coin
Watch and alert
About Hikma Pharmaceuticals
Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. The company operates through three segments: Injectables, Generics, and Branded. The Injectables segment provides generic and specialty injectable products primarily for use in hospitals. The Generics segment offers oral, respiratory, and other generic and specialty products for the retail market. The Branded segment offers branded generics and in-licensed products to retail and hospital markets. The company provides its products in various therapeutic areas, including respiratory, oncology, and pain management. It also offers its products in solid, semi-solid, liquid, and injectable final dosage forms. The company operates in the United Kingdom, rest of Europe, North America, the Middle East, North Africa, and internationally. Hikma Pharmaceuticals PLC was founded in 1978 and is headquartered in London, the United Kingdom.
- Headquarters:
- London, United Kingdom
- 52-week range:
- 0.0000 p – 1,865.00 p
- Website:
- hikma.com
Signals are generated automatically from price, volume and technical indicators. They are not investment advice.← Back to search
